Spectra Optia: what is this apheresis machine, and does it mean a clinic is safe?
The Spectra Optia separates blood so plasma can be removed and holds a 2007 FDA 510(k) clearance as a therapeutic blood separator. That clearance covers the device only. It names no diseases and does not show that longevity or detox uses work or that a clinic's team and protocol are sound.
Nov 17, 2026Updated Nov 18, 20267 min read

The Spectra Optia is an apheresis machine: it separates blood into its components so plasma can be removed. It holds a US FDA 510(k) clearance decided in 2007, so a clinic using it has recognized hospital equipment. The clearance does not show that a clinic's advertised use, such as longevity or detox, works, or that its team and protocol are sound.
What is the Spectra Optia, and what does an apheresis machine do?
The Spectra Optia is an apheresis system: equipment that draws blood, separates it, removes one part and returns the rest. In therapeutic plasma exchange (TPE), the machine separates blood "into red cells, white cells, platelets and plasma," and the plasma is discarded and replaced with a substitute fluid.
Plasma is the liquid part of blood, carrying antibodies and other circulating substances. In the rheumatic conditions the American College of Rheumatology (ACR) covers, the removed plasma "contains harmful antibodies," which is why taking it out can help.
The ACR says plasma exchange is typically performed in a hospital or infusion center, with a line in a large vein connected to "a specialized machine operated by a trained nurse." The Spectra Optia is one such machine and appears in published research, including a 2026 study of 114 patients who underwent TPE on the Spectra Optia Apheresis System. For the procedure itself, see how therapeutic plasma exchange works.
Is the Spectra Optia FDA-approved, and how does it compare with the Amicus?
The Spectra Optia is FDA-cleared, not FDA-approved for any use a clinic advertises. Its 510(k) record shows a decision of "Substantially Equivalent (SESE)" under the classification "Separator, Automated, Blood Cell And Plasma, Therapeutic," and that clearance applies to the device.
The record names a device, an applicant, a classification and a decision. Its review panel is listed as Gastroenterology/Urology. It names no diseases and says nothing about aging, longevity or detoxification.
The Amicus, a competing machine, has a record with the same structure and the same FDA product code, LKN:
- Spectra Optia, record K071079. Applicant: Gambro BCT, Inc., of Lakewood, Colorado. Device: "SPECTRA OPTIA APHERESIS SYSTEM, SPECTRA OPTIA EXCHANGE SET, MODEL 61000, 10200." Received 04/17/2007, decided 08/02/2007.
- Amicus, record K111702. Applicant: Fenwal, Inc., of Lake Zurich, Illinois. Device: "AMICUS SEPARATOR SYSTEM- USE IN THERAPEUTIC PLASMA EXCHANGE AND FILTER SET FOR AMICUS TPE." Received 06/17/2011, decided 03/22/2012, also Substantially Equivalent.
Company names on a machine or brochure today may differ from the applicant on a filing made years earlier. For a patient, the differences that matter usually lie in the team, the setting and the protocol, not the brand on the cabinet.
How does plasma exchange equipment differ from double filtration and INUSpheresis?
TPE removes your plasma and replaces it with a substitute fluid. Double filtration plasmapheresis (DFPP) instead filters the separated plasma and returns it, setting aside the material the filters catch.
Researchers describe that set-aside material as "eluate plasma from double filtration plasmapheresis procedures" or "sequestered plasma." Plasmapheresis is a broader term for procedures that separate plasma, and clinics do not always use it precisely.
| Approach | What happens to your plasma | Where it stands |
|---|---|---|
| Therapeutic plasma exchange (TPE) | Removed and discarded, replaced with substitute fluid | Graded disease by disease by the American Society for Apheresis |
| Double filtration plasmapheresis (DFPP) | Filtered and returned; filtered material set aside | Wellness uses rest on preliminary studies |
| Young-donor plasma infusion | Nothing removed; donor plasma is added | FDA says plasma is not FDA-approved to treat normal aging |
None of these is plasma donation, dialysis, platelet-rich plasma (PRP) or ozone therapy. If you are weighing a TPE clinic against an INUSpheresis centre, ask the centre which method it uses and what is removed, and see INUSpheresis vs plasma exchange, compared.
Does an FDA-cleared machine mean the treatment works for longevity or detox?
No. Whether a treatment helps depends on clinical evidence for that specific use: established for certain diseases, early for some new uses, and absent for longer life or fewer diseases in healthy people.
| Use | Status | What the sources show |
|---|---|---|
| Specific diseases | Established | ASFA's tenth edition has 93 fact sheets and 183 graded and categorized indications |
| Lipoprotein apheresis (not TPE) in selected heart patients | Established | Called "highly effective and well-established" |
| Microplastics, PFAS, epigenetic clocks, Alzheimer's | Emerging | Small, uncontrolled or company-tied studies; mixed results |
| Longevity or "detox" | Unproven | No study shows longer life or fewer diseases |
| Long COVID | Not supported | Sham-controlled trial found no benefit |
The American Society for Apheresis (ASFA) guideline summarizes the evidence for each disease separately. It is the reference to check when a clinic cites a condition.
What the emerging studies found
The microplastic, PFAS and epigenetic-clock studies measured blood levels or lab estimates, not health outcomes such as longer life or fewer diseases.
- Microplastics. Researchers mostly affiliated with Circulate Health measured blood microplastics before and after 174 one-plasma-volume TPE procedures and reported a reduction, with no comparison group shown in the abstract. They also write that "there is currently no established method for removing MP from the human body."
- PFAS. A paper whose authors include Ayus Medical Group staff and an Ayus advisory board member observed decreases in PFAS and microplastic levels after double filtration, though "responses varied across individuals and analytes," and "larger, well-designed clinical trials are needed." PFAS are chemicals that "bind strongly to serum albumin," according to a short single-author paper arguing TPE "may be a beneficial intervention." It notes that in a randomized trial of firefighters, regular plasma and whole blood donations significantly reduced serum PFAS.
- Epigenetic clocks, lab estimates of biological age. A trial of 42 individuals randomized to treatment arms or placebo reported "15 epigenetic clocks showing rejuvenation." Randomization "was based on entry date," and several authors are members of Circulate Inc.
- Alzheimer's. The Grifols-funded AMBAR trial randomized 347 patients and reported 52% less decline on a daily-living scale (P = .03), P = .06 on a cognitive scale, and "no changes in mild-AD patients."
What did not work
In long COVID, 50 patients were randomized to six sessions of TPE or a sham procedure, with "no diferences between groups in any of the efficacy parameters evaluated" (the misspelling is in the original). Separately, the FDA warned in 2019 of "no proven clinical benefit of the infusion of plasma from young donors" for aging or memory loss.
What are the risks, and can the machine or tubing matter?
Most TPE side effects are mild, such as feeling cold, nausea, tingling and fatigue; rarer problems include fainting, low calcium, low blood pressure, and infection or bleeding from a central line. The ACR lists:
- During a session, you may feel cold, nauseated, or experience mild tingling of the lips, hands or feet, with fatigue afterward common.
- "Very rarely, patients may feel light-headed or faint, have low calcium, vomiting, low blood pressure, or muscle cramps."
- A central line, a catheter placed in a large vein, carries "a small risk of infection and bleeding."
- "Plasma exchange can remove some medications," so timing matters for anyone on regular prescriptions.
For the rheumatic conditions it covers, the ACR says TPE is usually done every 2 to 3 days over 5 to 10 sessions; wellness schedules are set by clinics. More detail is in plasma exchange side effects and how serious they are.
The equipment mattered in one documented way. In the Spectra Optia microplastics study, the reduction was "obscured at low starting levels of MP because of leaching of MP back into the circulation from the plastic apheresis tubing set." No published comparison of safety between machine brands is cited here.
What should you ask a clinic about its equipment?
Ask which machine and procedure the clinic uses, who runs it, and what evidence supports your specific goal. The answers tell you more than the brand name.
- Which device do you use, and is this TPE (plasma removed and replaced) or double filtration (plasma filtered)?
- Is the device cleared in the US, and under what classification? May I see the record?
- Who operates the machine, and is a physician on site during the session?
- Will you use a central line or arm veins, and what is your infection-prevention routine?
- What replacement fluid do you use, and how do you manage calcium and blood pressure?
- How will you time my medications around sessions?
- Is my goal an ASFA-graded indication? If not, what study supports it, who funded it, and did it measure health outcomes or only blood levels?
- What will you measure before and after, and what would count as no benefit?
Bring the answers to a physician who knows your history before you book. Northvane's list of clinics offering plasma exchange shows who offers which procedure; it is not a ranking.
Common questions
What does a session on a Spectra Optia cost?
The machine brand does not set the price. What you pay depends on the clinic, the number of sessions, the replacement fluid and the setting, and wellness clinics price their own series. Compare full-series quotes rather than single sessions, and check what each includes. For dated figures, see what plasma exchange costs at clinics that publish prices.
Do the experts who write apheresis guidelines have ties to device makers?
Some do, and the guideline discloses it. The 2026 ASFA guideline lists authors who consult for or have received grants from Terumo BCT, and one who received a research grant from Asahi Kasei Medical. Disclosed ties are common in medical guidelines and do not by themselves invalidate the grading, but they are worth weighing alongside the evidence for each disease.
Sources11 cited
- [1]510(k) Premarket Notification · accessdata.fda.gov
- [2]Plasma Exchange (Plasmapheresis) | American College of Rheumatology · rheumatology.org
- [3]Can Plasma Exchange Be Used to Lower the Circulating Burden of Microplastics in Human Patients? · doi.org
- [4]510(k) Premarket Notification · accessdata.fda.gov
- [5]"sequestered plasma." · doi.org
- [6]Important Information about Young Donor Plasma Infusions for Profit | FDA · fda.gov
- [7]93 fact sheets and 183 graded and categorized indications · doi.org
- [8]Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. · doi.org
- [9]Role of Therapeutic Plasma Exchange in Accelerating the Clearance of Perfluoroalkyl and Polyfluoroalkyl Substances. · doi.org
- [10]42 individuals randomized to treatment arms or placebo · doi.org
- [11]A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. · doi.org
For information, not medical advice. Suggest a correction · Editorial policy


